[go: up one dir, main page]

MX2022013054A - Derivados de imidazolidinona y uso medico de los mismos. - Google Patents

Derivados de imidazolidinona y uso medico de los mismos.

Info

Publication number
MX2022013054A
MX2022013054A MX2022013054A MX2022013054A MX2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A MX 2022013054 A MX2022013054 A MX 2022013054A
Authority
MX
Mexico
Prior art keywords
medicine
derivative
present application
imidazolinone
imidazolinone derivative
Prior art date
Application number
MX2022013054A
Other languages
English (en)
Inventor
Jie Yan
Yang He
Yonggang Wei
Bing Liu
Hongzhu Chu
Guizhuan Su
Meiwei Wang
Yi Sun
Xuezhen Xu
Lvxue He
Feiquan Lei
Original Assignee
Chengdu Baiyu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Baiyu Pharmaceutical Co Ltd filed Critical Chengdu Baiyu Pharmaceutical Co Ltd
Publication of MX2022013054A publication Critical patent/MX2022013054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se relaciona con derivados de imidazolidinona y su uso médico, y en particular se relaciona con derivados de pirimidina representados por la fórmula general (I), o estereoisómeros, solvatos, metabolitos, profármacos, sales farmacéuticamente aceptables o cocristales de los mismos, una composición farmacéutica que comprende éstos, y el uso del compuesto o composición farmacéutica según la presente solicitud en la fabricación de un medicamento para el tratamiento del cáncer. (ver Fórmula).
MX2022013054A 2020-04-17 2021-04-16 Derivados de imidazolidinona y uso medico de los mismos. MX2022013054A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010302603 2020-04-17
CN202010679647 2020-07-15
CN202110360821 2021-04-02
PCT/CN2021/087912 WO2021209055A1 (zh) 2020-04-17 2021-04-16 咪唑啉酮衍生物及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2022013054A true MX2022013054A (es) 2022-11-09

Family

ID=78083933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013054A MX2022013054A (es) 2020-04-17 2021-04-16 Derivados de imidazolidinona y uso medico de los mismos.

Country Status (12)

Country Link
US (1) US20230165867A1 (es)
EP (1) EP4137491A4 (es)
JP (1) JP7498795B2 (es)
KR (1) KR20230004697A (es)
CN (1) CN114315834B (es)
AU (1) AU2021256235B2 (es)
BR (1) BR112022020962A2 (es)
CA (1) CA3175589A1 (es)
MX (1) MX2022013054A (es)
NZ (1) NZ793536A (es)
WO (1) WO2021209055A1 (es)
ZA (1) ZA202211870B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CN117321057A (zh) * 2021-08-23 2023-12-29 成都百裕制药股份有限公司 一种咪唑啉酮衍生物的制备工艺及其中间体
MX2024003693A (es) * 2021-09-23 2024-04-09 Chengdu Baiyu Pharmaceutical Co Ltd Forma cristalina del derivado de imidazolinona.
WO2024012516A1 (zh) 2022-07-13 2024-01-18 成都百裕制药股份有限公司 咪唑啉酮衍生物在联合放疗治疗肿瘤中的应用
JP2025531951A (ja) 2022-07-20 2025-09-26 カンバイダ （スーチュアン） バイオテクノロジー シーオー．， エルティーディー． 腫瘍の処置におけるドキソルビシンと組み合わせたイミダゾリノン誘導体の使用
JP2025539576A (ja) 2022-12-13 2025-12-05 カンバイダ （スーチュアン） バイオテクノロジー シーオー．， エルティーディー． イミダゾリノン化合物の医薬製剤、その調製方法及びその使用
WO2025049253A1 (en) * 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Bridged cycle‑based inhibitors of dna‑dependent protein kinase and compositions and application in gene editing
TW202513059A (zh) * 2023-09-21 2025-04-01 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物在製備用於聯合放療治療腫瘤的藥物中的應用及治療方法
WO2025191451A1 (en) * 2024-03-11 2025-09-18 Kangbaida (Sichuan) Biotechnology Co., Ltd. Imidazolinone derivative for use in the treatment of tumors in combination with rdc
WO2025196671A1 (en) * 2024-03-20 2025-09-25 Kangbaida (Sichuan) Biotechnology Co., Ltd. Imidazolinone derivative combined with pd-1 or pd-l1 inhibitor for use in the treatment of tumors
WO2025202996A1 (en) * 2024-03-29 2025-10-02 Kangbaida (Sichuan) Biotechnology Co., Ltd. Use of dna-pk inhibitor in preparation of a drug for use in the treatment of tumors
WO2025238615A1 (en) 2024-05-16 2025-11-20 Kangbaida (Sichuan) Biotechnology Co., Ltd. Combinations of heterocyclic dna-pk inhibitors and antibody-drug conjugates (adc) for use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298814A (zh) * 2007-08-23 2013-09-11 阿斯利康(瑞典)有限公司 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
US9708326B2 (en) 2013-02-25 2017-07-18 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US20140314673A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ755222A (en) 2016-12-20 2022-07-01 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
CN114315834A (zh) 2022-04-12
BR112022020962A2 (pt) 2022-12-06
US20230165867A1 (en) 2023-06-01
CA3175589A1 (en) 2021-10-21
CN114315834B (zh) 2024-01-05
JP7498795B2 (ja) 2024-06-12
EP4137491A4 (en) 2024-05-08
JP2023521923A (ja) 2023-05-25
AU2021256235B2 (en) 2024-05-09
AU2021256235A1 (en) 2022-11-17
KR20230004697A (ko) 2023-01-06
EP4137491A1 (en) 2023-02-22
WO2021209055A1 (zh) 2021-10-21
ZA202211870B (en) 2023-05-31
NZ793536A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
ZA202306652B (en) Five-membered ring derivative and medical use thereof
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
MX2023015533A (es) Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
PH12022551014A1 (en) Substituted tricyclic compounds
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2020000268A (es) Agonista de fxr.
ZA202400988B (en) Aak1 inhibitor and use thereof
ZA202311035B (en) Phosphonyl derivative, and composition and pharmaceutical application thereof
MX2021003655A (es) Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.
JP2013519653A5 (es)
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2024014628A (es) Compuesto para inhibir o degradar bcl6 y uso de este en farmacia
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2025007797A (es) Derivado de tetrahidrotiofeno y uso de este en medicina
ZA202501471B (en) Preparation and use of quinazolinone derivative as kinase inhibitor
MX2018008799A (es) Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica.
MX2021015827A (es) Antagonista de neurokinin -1.
MX2024000087A (es) Compuestos tiazol-lactama-espiroheterociclicos y sus aplicaciones.